HCPCS code J9051: Bortezomib injection, MAIA product, per 0.1 mg2026 Medicare rate & RVUs in California

CMS doesn’t publish an office rate for J9051 in California.

Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.

What J9051 covers

J9051 identifies injectable bortezomib associated with the MAIA product. Bortezomib is used in oncology treatment, including for multiple myeloma and mantle cell lymphoma, and may be administered intravenously or subcutaneously. The code distinguishes this product from other bortezomib products; use it when this product is administered.

CMS assigns status E, excluding the drug from the physician fee schedule. When Medicare covers it, payment is handled under another method; the HCPCS pricing method identifies it as a Part B drug generally priced from CMS quarterly ASP drug files. Coverage is left to the Medicare contractor's judgment. Each billing unit represents 0.1 mg of bortezomib, so the number of units reflects the administered dose divided by 0.1 mg.

This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.

Where J9051 pays more and less in California

The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.

29 of 29 payment localities

How the J9051 rate is calculated

Each of J9051’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.

Payment rules and modifiers for J9051

J9051 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.

J9051 compared with similar codes

How to choose

J9041Bortezomib injectionPer 0.1 mg

J9041 identifies a different bortezomib product. J9051 is specific to the MAIA product, which CMS identifies as not therapeutically equivalent to J9041.

J9048Bortezomib injectionFresenius Kabi, per 0.1 mg

J9048 identifies the Fresenius Kabi bortezomib product; J9051 identifies the MAIA product. Use the code matching the product administered.

J9054Bortezomib injectionBoruzu, per 0.1 mg

J9054 identifies Boruzu bortezomib, while J9051 identifies the MAIA product. These are separate product-specific codes.

Codes related to J9051

Related codes aren’t interchangeable: bill the code that matches the service performed.

Where these rates come from

FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.

CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027

Open CMS sourceHow we calculate rates